MatthewKutnyMD

Pediatric Hematology & Oncology • Birmingham, AL

Director, Clinical Trials Office, Children’s of Alabama

Join to view full profile

Dr. Kutny is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kutny's full profile

Already have an account?

Office
1600 7th Ave S
Birmingham, AL 35233
Phone+1 205-934-3795

Fax+1 205-975-8991

Education & Training

University of WashingtonFellowship, Pediatric Hematology/Oncology, 2008 - 2011
Vanderbilt University Medical CenterResidency, Pediatrics, 2005 - 2008
Vanderbilt University School of MedicineClass of 2005

Certifications & Licensure

AL State Medical License 2011 - 2024
WA State Medical License 2008 - 2013
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Start of enrollment: 2017 Nov 29
Active, not recruiting
Phase 3
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Start of enrollment: 2019 Jul 03
Recruiting
Phase 3
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

16 citations
Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Tran...
Katherine Tarlock, Maria Luisa Sulis, Joseph H Chewning, Jessica A Pollard, Todd Cooper
Transplantation and Cellular Therapy. 2022-09-01
42 citations
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
Matthew A. Kutny, Barry K. Moser, Kristina Laumann, James H. Feusner, Alan S. Gamis
Pediatric Blood & Cancer. 2012-10-01
39 citations
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAM...
Matthew A. Kutny, Todd A. Alonzo, Oussama Abla, Madhvi Rajpurkar, Robert B. Gerbing
JAMA Oncology. 2021-11-11

Press Mentions

Chemotherapy-Free Regimen Benefits Children with Acute Promyelocytic LeukemiaFebruary 2nd, 2022
A Gentler Standard for Acute Promyelocytic Leukemia in KidsNovember 11th, 2021
Arsenic Trioxide Consolidation Effective in Pediatric Acute Promyelocytic LeukemiaAugust 21st, 2017
Join now to see all